Toolkit
HIV Treatment and Care
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research toward a cure, and immune-based and gene therapies in development
Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda
People with mental disorders in low-income countries are at risk of being left behind during efforts to expand universal health coverage. Aim is to propose context-relevant strategies for moving towards universal health coverage for people with mental disorders in Ethiopia.
This research report provides results from the study on living conditions among people with disabilities in Zambia. Comparisons are made between individuals with and without disabilities and also between households with and without a disabled family member. Results obtained in Zambia are also compar...ed to those obtained in earlier studies carried out in Namibia, Zimbabwe and Malawi. The Zambian study was undertaken in 2005-2006.
more
Miscellaneous
Chapter J.8
Antibiotic resistant bacteria are spreading at an alarming rate and some bacterial infections may once again be untreatable. Antibiotic resistance (ABR), conservatively calculated, causes more than 500 000 deaths every year. This number is projected to rise dramatically if radical actions are not ta...ken. Lack of effective antibiotics, diagnostics and vaccines threatens the health of millions and hampers fulfilment of several of the Sustainable Devel- opment Goals. Access to effective antibiotics should be part of every adult and child’s right to health.
more
El ámbito de aplicación incluye a todos los trabajadores involucrados en trabajos de asistencia sanitaria (comprendidos los desarrollados en aislamiento, traslados, labores de limpieza, eliminación de residuos,etc.), así como los de transportes aéreo,marítimo y ferrocarril de ...larga distancia o internacional, los colectivos de rescate (bomberos, salvamento marítimo, policía, guardia civil, etc.), atención al público, hostelería, sector servicios, etc. Dado que el contacto con el virus puede afectar a entornos sanitarios y no sanitarios, corresponde a las empresas evaluar el riesgo de exposición y seguir las recomendaciones que sobre el particular emita el servicio de prevención,siguiendo las pautas y recomendaciones formuladas por las autoridades sanitarias.
more
9 June 2021
Since its launch, GLASS has expanded in scope and coverage and as of May 2021, 109 countries and territories worldwide have enrolled in GLASS. A key new component in GLASS is the inclusion of antimicrobial consumption (AMC) surveillance at the national level highlighted in this fourth G...LASS report.
The fourth GLASS report summarizes the 2019 data reported to WHO in 2020. It includes data on AMC surveillance from 15 countries and AMR data on 3 106 602 laboratory-confirmed infections reported by 24 803 surveillance sites in 70 countries, compared to the 507 923 infections and 729 surveillance sites reporting to the first data call in 2017.
The report also describes developments over the past years of GLASS and other AMR surveillance programmes led by WHO, including resistance to anti-human immunodeficiency virus and anti-tuberculosis medicines, antimalarial drug efficacy.
more
Against this background of nearly 20 years of experience of research, development and
improvement in patient safety, the role of incident and adverse event reporting, as well as the
benefits that derive from it, is still a work in progress.This document has two main purposes:
• to provide an up...-to-date perspective on patient safety incident reporting and
learning systems currently in place, including how to fill in existing gaps in these
systems;
• to provide practical guidance on the establishment and effective use of patient
safety incident reporting and learning systems.
more
The Lancet Volume 397, ISSUE 10269, P129-170, January 09, 2021
Operation update 01/04/2022